Europe opens market to Israeli medicines

Passed in European Parliament by vote of 379-230, pact will contribute to the elimination of technical trade barriers.

By
October 24, 2012 01:55
1 minute read.
DAVID SCHWAMMENTHAL

DAVID SCHWAMMENTHAL 370. (photo credit: Facebook)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

After a more than a two-year delay, the European Parliament approved a technical agreement pact on Tuesday that will make it easier to export Israeli pharmaceuticals.

The Agreements on Conformity Assessment and Acceptance of Industrial Products (ACAAs), which passed by a vote of 379-230, will contribute to the elimination of technical barriers to trade, thereby increasing the accessibility of the country’s pharmaceuticals to EU markets, and vice versa.

Be the first to know - Join our Facebook page.


An Israeli diplomatic source said some left-wing parliament members had held up the agreement for months because of political reasons.

Daniel Schwammenthal, director of the American Jewish Committee Transatlantic Institute in Brussels, welcomed the decision, though he bewailed that it had taken more than two years for the European Parliament to act on the measure that the heads of the 27 EU states had agreed on in March 2010.

“At its core, this was not a debate on the merits of the agreement. This was about politics,” Schwammenthal added.

“Some members of the European Parliament were putting their disagreements with Israel ahead of their obligations to ensure their constituents had fast access to the best and most affordable healthcare.”

He said that Israel’s pharmaceutical companies “are at the cutting edge of research, finding innovative treatments that help save lives and reduce suffering.

JPOST VIDEOS THAT MIGHT INTEREST YOU:


What’s more, through their leadership in the generics market, Israeli medicines help healthcare providers reduce spending while maintaining high quality standards.”

Schwammenthal stressed that “ACAA is simply about the interests of European patients.”

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The logo of Volvo is seen on the front grill of a Volvo truck in a customer showroom at the company'
September 24, 2018
Volvo halts Iran truck assembly due to U.S. sanctions

By REUTERS